Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Deutetrabenazine (Austedo) is a vesicular monoamine transporter 2 (VMAT2) inhibitor used in the treatment of chorea associated with Huntington's disease and tardive dyskinesia. It has shown potential antipsychotic activity with a reduced risk of inducing tardive dyskinesia, which is a significant complication of dopamine antagonist therapies.
• The information was derived from three systematic reviews/meta-analyses that provided evidence on Austedo's efficacy and safety, its comparison to other VMAT2 inhibitors like valbenazine, as well as strategies for preventing tardive dyskinesia.
• Compared to valbenazine, another VMAT2 inhibitor used for treating tardive dyskinesia, Austedo demonstrated efficacy at lower doses but requires more data regarding long-term outcomes. This suggests an area where further research could enhance understanding of Austedo’s effectiveness over time.
• Best practices include limiting use to specific conditions, minimizing effective doses and duration. When tardive dyskinesia occurs despite preventative measures, deutetrabenazine along with valbenzine have been recommended based on strong evidence supporting their use.
• While detailed subgroup analyses were not available, emphasis was placed on adult populations suffering from both Huntington's disease-related chorea and tardive dyskinesia when considering treatments using Austedo.
• Further research, especially focusing on long-term safety and efficacy, will be critical for fully understanding how deutetrabenazine can best serve patients dealing with conditions such as psychosis symptoms related to tardive dyskinesia or chorea associated with Huntington's Disease.